Form 4: Director James Wilson Executes Corcept Stock Transfers

Director James N. Wilson reported a series of internal share transfers between family trusts and partnerships.

Summary

• Director James N. Wilson transferred 892,056 shares of Corcept Therapeutics (CORT) common stock from the James and Pamela Wilson Family Partners.
• A total of 9,011 shares were transferred from the Family Partners to the James N. Wilson and Pamela D. Wilson Trust.
• The transactions were executed as gifts (G) with a price of $0.00 per share.
• The reporting person maintains indirect beneficial ownership through various family trusts and grantor retained annuity trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are purely administrative transfers between family-controlled entities.

Positives

• The transactions represent internal estate planning and rebalancing rather than open-market sales.
• The director maintains significant indirect beneficial ownership in the company.

Negatives

• Large volume transfers, even if internal, can sometimes signal changes in long-term estate planning or tax strategy.

Risks

• Concentration of voting power within family trusts and partnerships.

Future Outlook

No forward-looking guidance or operational outlook provided in this filing.

Industry Context

StockSavvy.ai notes that internal transfers between family-controlled entities are common among long-term directors and do not typically reflect a change in sentiment regarding the company's underlying business performance.

Comparison to Industry Standards

• The filing is consistent with standard SEC reporting requirements for directors managing personal and family holdings.

Related Party Transactions

• The filing discloses transfers between the James and Pamela Wilson Family Partners and the James N. Wilson and Pamela D. Wilson Trust.

Stakeholder Impact

• Minimal impact on shareholders as the total beneficial ownership remains within the reporting person's family control.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Director, Estate Planning